Scope and Purpose
To propose steps for creation of LIVD file entries for all IVD tests, available in a centralized repository with or without mapping review. Define the initial design and develop a sustainability and steady state plan for use of LIVD specifically and for other SHIELD standards in the future Ultimate goal is to have data used in patient care, research public health be comparable - need to have support for the full data model for the complete meaning of the test |
Items in scope:
|
Items out of scope:
|
Workplan
|
|
|
Declared Goals for LIDRLIDR represents what labs SHOULD use, provide coding for ALL aspects of what needs to be reported, including units of measure, which MUST match what is in the package insert and provide consistent units of measure for calculations (if not part of the package insert) |
Prior work: |
Call information
Every Monday 9-10 AM ET
Participants
Name | Organization | Role | |
---|---|---|---|
Hung Luu | UT Southwestern Medical Center | Working Group Co-Chair; SC liasion | |
Riki Merrick | Association of Public Health Laboratories | Working Group Co-Chair; SC liasion | |
Andrea Pitkus | University of Wisconsin-Madison | Steering Committee member | |
Xavier Gansel | Biomerieux | Steering Committee member | |
Rob Rae | CAP | ||
Dan Rutz | Epic | Steering Committee member | |
Pam Banning |
Solventum | |||
Laurent LARDIN | Biomerieux | ||
Amy McCormick | Epic | ||
Sandy Jones | CDC Cancer Surveillance | ||
Stan Huff | Graphite | Steering Committee member | |
Craig Collom | Steering Committee member | ||
Marti Velezis | Sonrisa/FDA | ||
Walter Sujanski | FDA | Observer | |
Raja Cholan | FDA | Observer | |
Russ Ott | FDA | Observer |
Operational Definitions
Name (Acronym)
Definition
Akila Namasivayam | FDA | Observer | |
Paul Rogers | FDA | Observer | |
Dong Wang | FDA | Observer |
Operational Definitions - see SHIELD Glossary
Projects
Project Name [include link to the filled out project template file, if created] | Brief Description | Priority |
---|---|---|
Compile the requirements for LIDR - functional/policy/starting content/sustainability and develop and document the process for adding NEW | 1 | |
Additional data elements for LIVD file (e.g. UDI for equipment/ reagents, harmonization methods, UDIs for devices/kits/reagents | this is defining the WHAT elements are needed in LIDR - it will inform the requirements above, where we need to define the process of HOW to add new elements, when those are identified | 2 |
Clinically relevant test definitions - what makes results “co-minglable” | How are results identified that are comparable (apples) or not comparable (oranges) How is said identification mechanism implemented? | 3 |